>印度社区获得性肺炎药物市场，按产品（大环内酯类、B-内酰胺抗生素、喹诺酮类、四环素类、卡巴培南类、糖肽类抗生素、截短侧耳素等）、给药途径（口服和静脉注射）、剂量（药片和溶液）、产品类型（仿制药和品牌药）、购买方式（处方药和非处方药）、类型（细菌、病毒和真菌）、人群类型（儿童、老年病学和成人）、最终用户（医院、专科诊所、家庭护理等）、分销渠道（医院药房、零售药房、网上药房等）划分 - 行业趋势和预测到 2031 年。
印度社区获得性肺炎药物市场分析与洞察
推动市场增长的主要因素之一是肺炎患病率的上升。此外，意识的提高和医疗支出的增加是推动市场增长的另一个关键因素。然而，与药品相关的可负担性和价格敏感性正在制约市场的增长。技术驱动的解决方案和创新有望成为市场增长的机会。然而，有限的医疗基础设施和渠道可能会对市场增长造成挑战。
Data Bridge Market Research 分析，印度社区获得性肺炎药物市场预计将从 2023 年的 9272 万美元增至 2031 年的 1.6352 亿美元，在 2024 年至 2031 年的预测期内以 7.5% 的复合年增长率增长。
|
报告指标 |
细节 |
|
预测期 |
2024 至 2031 年 |
|
基准年 |
2023 |
|
历史岁月 |
2022（可定制为 2016 – 2021） |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
产品（大环内酯类、β-内酰胺类抗生素、喹诺酮类、四环素类、卡巴培南类、糖肽类抗生素、截短侧耳素等）、给药途径（口服和静脉注射）、剂量（片剂和溶液）、产品类型（仿制药和品牌药）、购买方式（处方药和非处方药）、类型（细菌、病毒和真菌）、人群类型（儿童、老年人和成人）、最终用户（医院、专科诊所、家庭护理等）、分销渠道（医院药房、零售药房、网上药房等） |
|
覆盖国家 |
印度 |
|
涵盖的市场参与者 |
辉瑞公司、西普拉公司、阿斯利康、雅培、梯瓦制药工业有限公司、诺华公司、费森尤斯卡比、百特和美国阿拉宾度制药公司等 |
市场定义
社区获得性肺炎 (CAP) 是指在医院或医疗机构之外感染的一种肺炎。它是一种常见的传染病，其特征是因感染细菌、病毒、真菌或其他病原体而导致肺组织发炎。CAP 影响所有年龄段的人，但在儿童、老年人以及患有基础疾病或免疫系统受损的人中尤其常见。
印度社区获得性肺炎药物市场动态
本节旨在了解市场驱动因素、机遇、限制因素和挑战。下文将详细讨论所有这些内容：
司机
- 肺炎发病率上升
印度肺炎的患病率和负担不断上升，为该国社区获得性肺炎 (CAP) 药物市场提供了巨大的机会。肺炎是发病和死亡的主要原因，尤其是在儿童和老年人等弱势群体中，因此对有效且可获得的治疗的需求日益增加。这种日益增长的需求为制药公司创造了市场机会，可以创新、开发和提供各种肺炎药物，以应对与该疾病相关的不断变化的菌株和挑战。
- 抗生素耐药性日益严重 引发肺炎病原体
引起肺炎的抗生素耐药病原体数量不断增长，这是印度社区获得性肺炎 (CAP) 药物市场的一个独特特点。随着抗生素耐药性成为全球关注的问题，迫切需要创新有效的治疗方法来对抗不断演变的微生物威胁。印度制药业蓬勃发展，有潜力在新型抗生素和替代疗法的开发方面处于领先地位。印度制药公司可以通过投资研发来应对抗生素耐药菌株，为全球医疗保健领域贡献宝贵的解决方案。此外，优先研究抗生素管理和联合疗法的举措可以进一步提高印度在解决肺炎治疗中抗生素耐药性这一复杂问题方面的地位。
机会
- 技术驱动的解决方案和创新
利用人工智能、数据分析和远程医疗等先进技术可以简化医疗保健系统的各个方面。这包括改进诊断能力、个性化治疗计划和高效的肺炎药物供应链管理。此外，药物开发中的创新方法，例如新配方或药物输送系统，可以提高疗效和患者对治疗的依从性。采用数字平台进行医疗保健服务，包括远程患者监控和虚拟咨询，可以克服地理障碍，确保即使是农村人口也能及时获得医疗干预。拥抱技术不仅可以提高医疗保健服务的整体效率，还可以使印度成为医疗保健创新的领导者，促进 CAP 药物市场在国内和全球舞台上的进步。技术与医疗保健的融合为印度创造了一个更具弹性、更易于访问和以患者为中心的市场的机会。
限制/挑战
- 与药物相关的可负担性和价格敏感性
由于社会经济状况各异，大量人口面临不同程度的经济限制，药物成本成为医疗保健可及性的关键因素。肺炎是一种常见的呼吸道感染，需要及时有效的治疗，但与药品相关的经济负担可能会阻碍患者及时寻求必要的药物。人群对价格的敏感性，加上 CAP 的高患病率，对制药公司提出了挑战，即在提供优质药物和确保其对广大人口具有经济可行性之间取得平衡。负担能力限制可能导致治疗延迟或不充分，影响健康结果，并可能导致肺炎相关发病率和死亡率在印度持续存在。
- 医疗保健基础设施和渠道有限
缺乏可获得的医疗保健服务导致个人难以获得及时和优质的医疗服务，包括各种健康状况的诊断和治疗。
基础设施和获取途径的这种限制可能导致医疗干预延迟、健康问题恶化和可预防疾病负担增加。个人可能面临及时到达医疗机构、进行必要的诊断测试和获取适当的肺炎药物的挑战。
最新动态
- 2023 年 9 月，阿斯利康获得印度中央药品标准控制组织 (CDSCO) 的批准，进口和销售一种预防呼吸道合胞病毒的药物。这将有助于该公司加强其在印度市场的地位
- 2021 年 5 月，Teva Pharmaceutical Industries Ltd. 宣布推出 250 毫克和 500 毫克强度的仿制红霉素片，这是 Arbor Pharmaceuticals 的参考上市药物 (RLD) 红霉素片的治疗等效药物。这有助于该公司加强其产品组合
印度社区获得性肺炎药物市场范围
印度社区获得性肺炎药物市场根据产品、给药途径、剂量、产品类型、购买方式、类型、人群类型、最终用户和分销渠道分为九个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
产品
- 大环内酯类
- B-内酰胺抗生素
- 喹诺酮类
- 四环素
- 卡巴培南
- 糖肽抗生素
- 截短侧耳素
- 其他的
根据产品，市场分为大环内酯类、β-内酰胺类抗生素、喹诺酮类、四环素类、卡巴培南类、糖肽类抗生素、截短侧耳素等。
给药途径
- 口服
- 静脉
根据给药途径，市场分为口服和静脉注射。
剂量
- 药片
- 解决方案
根据剂量，市场分为片剂和溶液。
产品类型
- 泛型
- 品牌
根据产品类型，市场分为仿制药和品牌药。
购买方式
- 处方
- 场外交易
根据购买方式，市场分为处方药和非处方药。
类型
- 细菌
- 病毒
- 真菌
根据类型，市场分为细菌、病毒和真菌。
人口类型
- 孩子们
- 老年病学
- 成年人
根据人口类型，市场分为儿童、老年人和成人。
最终用户
- 医院
- 专科诊所
- 家庭护理
- 其他的
根据最终用户，市场分为医院、专科诊所、家庭护理和其他。
分销渠道
- 医院药房
- 零售药店
- 网上药店
- 其他的
根据分销渠道，市场分为医院药房、零售药房、网上药房和其他。
印度社区获得性肺炎药物市场竞争格局及份额分析
印度社区获得性肺炎药物市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品批准、产品宽度和广度、应用主导地位以及产品类型生命线曲线。以上提供的数据点仅与公司对市场的关注有关。
该市场的一些主要市场参与者包括辉瑞公司、西普拉公司、阿斯利康、雅培、梯瓦制药工业有限公司、诺华公司、费森尤斯卡比、百特和美国阿拉宾度制药公司等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES
5 REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF PNEUMONIA
6.1.2 GROWING ANTIBIOTIC RESISTANCE PATHOGENS DRUGS
6.1.3 INCREASING HEALTHCARE AWARENESS AND EXPENDITURE
6.1.4 GROWING DEMAND FOR GENERIC AND LOCALLY PRODUCED DRUGS
6.2 RESTRAINTS
6.2.1 AFFORDABILITY AND PRICE SENSITIVITY ASSOCIATED WITH THE DRUGS
6.2.2 UNEQUAL DISTRIBUTION OF HEALTHCARE RESOURCES IN DIFFERENT LOCALITY
6.2.3 PIPELINE OF NEW ANTIBIOTIC DEVELOPMENT
6.3 OPPURTUNITIES
6.3.1 TECHNOLOGY-DRIVEN SOLUTIONS AND INNOVATION
6.3.2 FOCUS ON AFFORDABILITY AND GENERICS OF THE PNEUMONIA DRUGS
6.3.3 FOCUS ON LEVERAGING TELEMEDICINE AND SPECIFIC AGED PATIENT
6.4 CHALLENGES
6.4.1 LIMITED HEALTHCARE INFRASTRUCTURE AND ACCESS
6.4.2 ANTIBIOTIC RESISTANCE AND COUNTERFEITING IN PHARMACEUTICAL DRUGS
7 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 MACROLIDES
7.2.1 AZITHROMYCIN
7.2.2 ERYTHROMYCIN
7.2.3 CLARITHROMYCIN
7.2.4 OTHERS
7.3 B-LACTAM ANTIBIOTICS
7.3.1 CEPHALOSPORIN
7.3.1.1 THIRD GENERATION CEPHALOSPORIN
7.3.1.2 SECOND GENERATION CEPHALOSPORIN
7.3.1.3 FOURTH GENERATION CEPHALOSPORIN
7.3.1.4 FIRST GENERATION CEPHALOSPORIN
7.3.2 AMOXICILLIN AND CLAVULANATE POTASSIUM
7.3.3 PIPERACILLIN AND TAZOBACTAM
7.3.4 AMPICILLIN AND SULBACTAM
7.3.5 OTHERS
7.4 QUINOLONES
7.4.1 MOXIFLOXACIN
7.4.2 LEVOFLOXACIN
7.4.3 GEMIFLOXACIN
7.4.4 GATIFLOXACIN
7.4.5 CIPROFLOXACIN
7.4.6 DELAFLOXACIN
7.4.7 OTHERS
7.5 TETRACYCLINE
7.5.1 DOXYCYCLINE
7.5.2 OMADACYCLINE
7.5.3 OTHERS
7.6 CARBAPENEM
7.6.1 IMIPENEM
7.6.2 MEROPENEM
7.6.3 ERTAPENEM
7.7 GLYCOPEPTIDE ANTIBIOTICS
7.7.1 VANCOMYCIN
7.7.2 TEICOPLANIN
7.7.3 OTHERS
7.8 PLEUROMUTILIN
7.9 OTHERS
8 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 ORAL
8.3 INTRAVENOUS
9 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY DOSAGE
9.1 OVERVIEW
9.2 TABLET
9.3 SOLUTION
10 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY PRODUCT TYPE
10.1 OVERVIEW
10.2 GENERICS
10.3 BRANDED
11 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY MODE OF PURCHASE
11.1 OVERVIEW
11.2 PRESCRIPTION
11.3 OTC
12 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE
12.1 OVERVIEW
12.2 BACTERIAL
12.3 VIRUS
12.4 FUNGI
13 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY POPULATION TYPE
13.1 OVERVIEW
13.2 CHILDREN
13.3 GERIATRICS
13.4 ADULTS
14 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 HOME CARE
14.5 OTHERS
15 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 HOSPITAL PHARMACY
15.3 RETAIL PHARMACY
15.4 ONLINE PHARMACY
15.5 OTHERS
16 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: INDIA
17 SWOT ANALYSIS
18 COMPANY PROFILES
18.1 PFIZER INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 PRODUCT PORTFOLIO
18.1.4 RECENT DEVELOPMENT
18.2 CIPLA INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 PRODUCT PORTFOLIO
18.2.4 RECENT DEVELOPMENT
18.3 ASTRAZENECA
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 PRODUCT PORTFOLIO
18.3.4 RECENT DEVELOPMENT
18.4 ABBOTT
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 PRODUCT PORTFOLIO
18.4.4 RECENT DEVELOPMENT
18.5 TEVA PHARMACEUTICAL INDUSTRIES LTD.
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENTS
18.6 AUROBINDO PHARMA USA
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.7 BAXTER
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 FRESENIUS KABI
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENT
18.9 NOVARTIS AG
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
表格列表
TABLE 1 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 2 INDIA MACROLIDES IN COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 3 INDIA B-LACTAM ANTIBIOTICS IN COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 4 INDIA CEPHALOSPORIN IN COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 5 INDIA QUINOLONES IN COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 6 INDIA TETRACYCLINE IN COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 7 INDIA CARBAPENEM IN COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 8 INDIA GLYCOPEPTIDE ANTIBIOTICS IN COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 9 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 10 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY DOSAGE, 2022-2031 (USD MILLION)
TABLE 11 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 12 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY MODE OF PURCHASE 2022-2031 (USD MILLION)
TABLE 13 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 14 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY POPULATION TYPE, 2022-2031 (USD MILLION)
TABLE 15 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 16 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
图片列表
FIGURE 1 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: SEGMENTATION
FIGURE 2 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: DROC ANALYSIS
FIGURE 4 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: COUNTRYWISE MARKET ANALYSIS
FIGURE 5 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF PNEUMONIA IS DRIVING THE GROWTH OF THE INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET FROM 2024 TO 2034
FIGURE 12 MACROLIDES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET IN 2024 TO 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL RAPID DIAGNOSTIC TESTS (RTD) MARKET
FIGURE 14 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY PRODUCT, 2023
FIGURE 15 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY PRODUCT, 2024-2031 (USD MILLION)
FIGURE 16 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY PRODUCT, CAGR (2024-2031)
FIGURE 17 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 18 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 19 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
FIGURE 20 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 21 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 22 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY DOSAGE, 2023
FIGURE 23 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY DOSAGE, 2024-2031 (USD MILLION)
FIGURE 24 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY DOSAGE, CAGR (2024-2031)
FIGURE 25 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY DOSAGE, LIFELINE CURVE
FIGURE 26 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY PRODUCT TYPE, 2023
FIGURE 27 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION)
FIGURE 28 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY PRODUCT TYPE, CAGR (2024-2031)
FIGURE 29 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 30 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY MODE OF PURCHASE, 2023
FIGURE 31 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
FIGURE 32 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY MODE OF PURCHASE, CAGR (2024-2031)
FIGURE 33 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 34 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY TYPE, 2023
FIGURE 35 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 36 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 37 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 38 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY POPULATION TYPE, 2023
FIGURE 39 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY POPULATION TYPE, 2024-2031 (USD MILLION)
FIGURE 40 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY POPULATION TYPE, CAGR (2024-2031)
FIGURE 41 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 42 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY END USER, 2023
FIGURE 43 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 44 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY END USER, CAGR (2024-2031)
FIGURE 45 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 46 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 47 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 48 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 49 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 50 INDIA COMMUNITY ACQUIRED PNEUMONIA DRUGS MARKET: COMPANY SHARE 2023 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
